{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:00:56Z","timestamp":1767135656662,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd006719.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T00:00:00Z","timestamp":1232496000000}}],"reference-count":38,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006719.pub3","type":"journal-article","created":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T12:19:45Z","timestamp":1233663585000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Alkylating agents for Waldenstrom's macroglobulinaemia"],"prefix":"10.1002","volume":"2010","author":[{"given":"Kun","family":"Yang","sequence":"first","affiliation":[{"name":"West China Hospital, Sichuan University; Chinese Cochrane Centre, Chinese EBM Centre; No. 37, Guo Xue Xiang Chengdu China 610041"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianlong","family":"Tan","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Chinese Cochrane Centre, Chinese EBM Centre; No. 37, Guo Xue Xiang Chengdu China 610041"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taixiang","family":"Wu","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Chinese Cochrane Centre, Chinese EBM Centre; No. 37, Guo Xue Xiang Chengdu China 610041"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,21]]},"reference":[{"key":"10.1002\/14651858.CD006719.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood.V98.9.2640","article-title":"Multicenter, randomized comparative trial of fludarabine and the combination of cyclophamide-doxorbicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease","volume":"98","author":"Leblond","year":"2001","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/sj.leu.2402221","article-title":"Evaluating treatment strategies in advanced Waldenstrom macroglobulinemia: use of quality-adjusted survival analysis","volume":"15","author":"Levy","year":"2001","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3109\/02841869009091789","article-title":"Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group","volume":"29","author":"Andersen","year":"1990","journal-title":"Acta Oncologica"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/1097-0142(19811115)48:10<2211::AID-CNCR2820481016>3.0.CO;2-5","article-title":"Alterations of peripheral blood B-lymphocyte populations in plasma cell disorders","volume":"48","author":"Dillman","year":"1981","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/1042819031000077025","article-title":"Treatment of Waldenstrom's Macroglobulinemia with the Combination of Fludarabine and Cyclophosphamide","volume":"44","author":"Dimopoulos","year":"2003","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood.V83.10.2939.2939","article-title":"Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility","volume":"83","author":"Gobbi","year":"1994","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/1097-0142(19810915)48:6<1302::AID-CNCR2820480609>3.0.CO;2-Q","article-title":"Malignant Lymphoma Supervening in Chronic Lymphomatic Leukemia and Related Disorders","volume":"48","author":"Harousseau","year":"1981","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2141.2000.01918.x","article-title":"Waldenstroem macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil","volume":"108","author":"Kyle","year":"2000","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/cncr.21882","article-title":"Fludarabine, cyclophosphamide,and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma","volume":"106","author":"Tam","year":"2006","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3816\/CLM.2005.n.015","article-title":"CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia","volume":"5","author":"Treon","year":"2005","journal-title":"Clinical Lymphoma"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00277-004-0858-7","article-title":"High incidence of complication after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies","volume":"83","author":"Neste","year":"2004","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0145-2126(90)90159-7","article-title":"Prognostic Significance of Glucocorticoid Receptor Determination in Patients with Chronic lymphocytic Leukemia and Immunocytoma-Lack of a Positive Correlation between Receptor Levels and Clinical Responsiveness","volume":"14","author":"Weiss","year":"1990","journal-title":"Leukemia Research"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1080\/1042819042000219502","article-title":"Effectiveness of Fludarabine, Idarubicin and Cyclophosphamide(FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin's Lymphoma","volume":"45","author":"Zanzani","year":"2004","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0014|cit14","unstructured":"Eastern Cooperative Oncology Group Phase II Pilot Study Of Rituximab Plus CHOP In Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia NCT00060346 in the registration of ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0015|cit15","unstructured":"German CLL Study Group Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia FlFludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia NCT00281983 in the registration of ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3816\/CLM.2005.n.020","article-title":"Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders","volume":"5","author":"Johnson","year":"2005","journal-title":"Clinical Lymphoma"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cncr.20826","article-title":"Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis","volume":"103","author":"Annibali","year":"2005","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/07357909109032794","article-title":"Waldenstrom's macroglobulinemia: long-term results with the M-2 protocol","volume":"9","author":"Case","year":"1991","journal-title":"Cancer Investigation"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/annonc\/mdh128","article-title":"Treatment for Waldenstrom's macroglobulinemia","volume":"15","author":"Chen","year":"2004","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.V83.6.1452.1452","article-title":"Waldenstrom's macroglobulinemia","volume":"83","author":"Dimopoulos MA. Alexanian","year":"1994","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2000.18.1.214","article-title":"Waldenstrom's macroglobulinemia :Clinical features, complications, and management","volume":"18","author":"Dimopoulos","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2005.03.144","article-title":"Diagnosis and Management of Waldenstrom's Macroglobulinemia","volume":"23","author":"Dimopoulos","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.1993.11.8.1553","article-title":"Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases","volume":"11","author":"Facon","year":"1993","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","article-title":"Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma","volume":"17","author":"Foran","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1634\/theoncologist.5-1-63","article-title":"Waldenstrom's Macroglobulinemia","volume":"5","author":"Gertz","year":"2000","journal-title":"The Oncologist"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ajh.20363","article-title":"Waldenstrom Macroglobulinemia: A Review of Therapy","volume":"79","author":"Gertz","year":"2005","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0028|cit28","first-page":"1078","article-title":"Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994","volume":"82(6)","author":"Groves FD. Travis LB. Devesa SS. Ries LA. Fraumeni","year":"1998","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V82.10.3148.3148","article-title":"Incidence of Waldenstrom's macroglobulinemia","volume":"82(10)","author":"Herrinton LJ. Weiss","year":"1993","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.2830150111","article-title":"Waldenstrom macroglobulinemia terminating in acute leukemia: a report of three cases","volume":"15","author":"Horsman","year":"1983","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.3748\/wjg.v12.i47.7676","article-title":"Meta-analysis of short-term outcomes after laparoscopy-assisted distal gastrectomy","volume":"12","author":"Hosono","year":"2006","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1586\/14737140.6.3.329","article-title":"Advances in the treatment of Waldenstrom's macroglobulinemia","volume":"6(3)","author":"Johnson","year":"2006","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2796.1989.tb01422.x","article-title":"Waldenstrom's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients","volume":"226","author":"Petrucci","year":"1989","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD006719.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/sonc.2003.50070","article-title":"2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia","volume":"30","author":"Weber","year":"2003","journal-title":"Seminars in Oncology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006719.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T13:46:47Z","timestamp":1753105607000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006719.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2009,1,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006719.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,21]]}}}